后弹力层内皮角膜移植术:安全性与结局:美国眼科学会报告
该报告由美国眼科学会基于截至2017年5月的文献综述评估后弹力层内皮角膜移植术(DMEK)治疗角膜内皮功能障碍的安全性与结局。DMEK术后平均最佳矫正视力为20/21至20/31,6个月时37.6%至85%的眼达到20/25或更好,平均内皮细胞丢失33%;最常见并发症为部分移植物脱位需注气(平均28.8%)。证据支持DMEK是安全有效的治疗,在视力恢复时间、视力结局和排斥率方面似优于后弹力层剥离内皮角膜移植术(DSEK)。
要点
- DMEK术后平均最佳矫正视力20/21至20/31,6个月时37.6%至85%的眼达20/25或更好。
- DMEK最常见并发症为部分移植物脱位需注气,平均28.8%(范围0.2%-76%)。
- DMEK在视力恢复时间、视力结局和排斥率方面似优于DSEK,且诱导的屈光误差更小。
核心结论
- 综述证据支持DMEK是治疗内皮性角膜失败的安全有效方法。
- 在视力恢复时间、视力结局和排斥率方面,DMEK似优于DSEK,且与DSEK相比诱导的屈光误差更小、手术风险和内皮细胞丢失相似。
- 在DMEK学习曲线之后,DMEK与DSEK的注气率和重复角膜移植率相似。
研究设计与样本
- 美国眼科学会报告,基于PubMed和Cochrane Library数据库截至2017年5月的文献检索,限英文摘要,共检索到1085篇文章,专家组审阅摘要后确定47篇与本评估相关。
主要发现
- DMEK术后平均最佳矫正视力为20/21至20/31,随访5.7至68个月;6个月时37.6%至85%的眼达到20/25或更好,17%至67%的眼达到20/20或更好。
- DMEK术后6个月平均内皮细胞丢失33%(范围25%-47%),等效球镜总变化+0.43屈光度(D;范围-1.17至+1.2 D),诱导散光极小为+0.03 D(范围-0.03至+1.11 D)。
- DMEK最常见并发症为部分移植物脱位需注气(平均28.8%;范围0.2%-76%),其次为眼压升高(范围0%-22%)、原发性移植物失败(平均1.7%;范围0%-12.5%)、继发性移植物失败(平均2.2%;范围0%-6.3%)和免疫排斥(平均1.9%;范围0%-5.9%)。
- DMEK末次随访时总移植物存活率为92%至100%;DSEK术后9个月最佳矫正视力为20/34至20/66,6个月平均内皮细胞丢失37%。
- DSEK最常见并发症为移植物脱位(平均14%;范围0%-82%)、内皮排斥(平均10%;范围0%-45%)和原发性移植物失败(平均5%;范围0%-29%)。
关键数值与推荐
- DMEK术后6个月37.6%至85%的眼最佳矫正视力达20/25或更好,17%至67%的眼达20/20或更好。
- DMEK术后6个月平均内皮细胞丢失33%(范围25%-47%),DSEK术后6个月平均内皮细胞丢失37%。
- DMEK部分移植物脱位需注气平均28.8%(范围0.2%-76%),DSEK移植物脱位平均14%(范围0%-82%)。
- DMEK原发性移植物失败平均1.7%(范围0%-12.5%)、继发性移植物失败平均2.2%(范围0%-6.3%)、免疫排斥平均1.9%(范围0%-5.9%)。
- DSEK原发性移植物失败平均5%(范围0%-29%)、内皮排斥平均10%(范围0%-45%)。
临床怎么用
- 原文结论支持DMEK作为内皮性角膜失败的安全有效治疗,但未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review the published literature on the safety and outcomes of Descemet membrane endothelial keratoplasty (DMEK) for the surgical treatment of corneal endothelial dysfunction. METHODS: Literature searches were last conducted in the PubMed and the Cochrane Library databases most recently in May 2017. The searches, which were limited to English-language abstracts, yielded 1085 articles. The panel reviewed the abstracts, and 47 were determined to be relevant to this assessment. RESULTS: After DMEK surgery, the mean best-corrected visual acuity (BCVA) ranged from 20/21 to 20/31, with follow-up ranging from 5.7 to 68 months. At 6 months, 37.6% to 85% of eyes achieved BCVA of 20/25 or better and 17% to 67% achieved BCVA of 20/20 or better. Mean endothelial cell (EC) loss was 33% (range, 25%-47%) at 6 months. Overall change in spherical equivalent was +0.43 diopters (D; range, -1.17 to +1.2 D), with minimal induced astigmatism of +0.03 D (range, -0.03 to +1.11 D). The most common complication was partial graft detachment requiring air injection (mean, 28.8%; range, 0.2%-76%). Intraocular pressure elevation was the second most common complication (range, 0%-22%) after DMEK, followed by primary graft failure (mean, 1.7%; range, 0%-12.5%), secondary graft failure (mean, 2.2%; range, 0%-6.3%), and immune rejection (mean, 1.9%; range, 0%-5.9%). Overall graft survival rates after DMEK ranged from 92% to 100% at last follow-up. Best-corrected visual acuity after Descemet's stripping endothelial keratoplasty (DSEK) ranged from 20/34 to 20/66 at 9 months. The most common complications after DSEK were graft detachment (mean, 14%; range, 0%-82%), endothelial rejection (mean, 10%; range, 0%-45%), and primary graft failure (mean, 5%; range, 0%-29%). Mean EC loss after DSEK was 37% at 6 months. CONCLUSIONS: The evidence reviewed supports DMEK as a safe and effective treatment for endothelial failure. With respect to visual recovery time, visual outcomes, and rejection rates, DMEK seems to be superior to DSEK and to induce less refractive error with similar surgical risks and EC loss compared with DSEK. The rate of air injection and repeat keratoplasty were similar in DMEK and DSEK after the learning curve for DMEK.
引用
- Deng SX, Lee WB, Hammersmith KM, et al. Descemet Membrane Endothelial Keratoplasty: Safety and Outcomes: A Report by the American Academy of Ophthalmology. Ophthalmology. 2017. PMID: 28923499. doi:10.1016/j.ophtha.2017.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。